Shenzhen Hepalink Pharma paid $13 million for a 42% stake in Canada’s OncoQuest and the two companies are in talks for a $5 million China JV; Shanghai’s ZAI Lab in-licensed China rights to a novel lung cancer drug candidate from Hanmi Pharma of Korea; Lee’s Pharma acquired China commercialization rights to an anti-nausea patch product from Solasia Pharma of Tokyo; Hong Kong’s Uni-Bio Science acquired worldwide rights to make and commercialize Jiangsu Hansoh Pharma’s mitiglinide, an oral type 2 diabetes treatment; and BGI, the Shenzhen-based genomics sequencing company, has re-purposed its US subsidiary, Complete Genomics of Mountain View, California, reducing staff significantly.
